It seems Gilead is selling tons
of Atripla these days:
Gilead 4Q Profit Rises 43 Percent On Atripla Sales
Gilead Sciences said yesterday its profit climbed 43 percent in the fourth quarter due to rising sales of its three-in-one HIV drug Atripla. The company said sales of Atripla, which was approved in the U.S. in July 2006, jumped 50 percent compared to the fourth quarter of 2008. It said Atripla became its best-selling drug during the quarter, as revenue surpassed that of an older drug, Truvada. Gilead said its profit rose to $802.2 million, or 87 cents per share, from $560 million, or 59 cents per share.
Atripla is a 3-drug combo pill that includes Bristol-Myers Squibb’s Sustiva, a potent non-nuke that often causes vivid dreams (and more rarely other central nervous system side effects) -- thus the headline of this post.
Gilead is now the biggest seller of AIDS drugs in the world, selling a whopping $5.84 billion of antivirals last year.
I certainly hope they’re giving back to affected communities -- generously and often. We all know Gilead has long-standing grants and charitable giving programs, but they should grow in proportion to their HIV sales. I’ve seen no evidence that they have.